Biogen Inc. · NASDAQ:BIIB
Biogen — Biogen Idec — 38th Annual dbAccess Health Care Conference 2013
24 slides from Biogen's conference presentation, May 30, 2013
Slide 1: Biogen Idec 38th Annual dbAccess Health Care Conference
TITLE OF PRESENTATION BIOGEN IDEC 38TH ANNUAL dbACCESS HEALTH CARE CONFERENCE BOSTON, MA MAY 30, 2013
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, including statements about our growth prospects, regulatory filings and agency actions, product launch plans and the anticipated timing thereof, our intellectual property, data and other proprietary rights, the anticip
Slide 3: Consistently Strong Financial Performance
Consistently Strong Financial Performance Non-GAAP Diluted EPS ($) 2.74 3.66 4.12 5.15 5.90 6.53 2007 2008 2009 2010 2011 2012 Free Cash Flow ($M) 735 1,286 909 1,452 1,520 1,625 2007 2008 2009 2010 2011 2012 +17% CAGR +19% CAGR 3.2 4.1 4.4 4.7 5.0 5.5 2007 2008 2009 2010 2011 2012 Revenues ($B) +11
Slide 4: Pillars of Near and Long-term Growth
Pillars of Near and Long-term Growth Revitalized Pipeline & R&D • Maturing Pipeline • Advanced target discovery • Novel academic consortia • Innovative science New Potential Product Launches • PLEGRIDYTM • ELOCTATETM • ALPROLIXTM Core Business • AVONEX ® • TYSABRI ® • TECFIDERATM • FAMPYRA® • RITUXA
Slide 5: Pillars of Near and Long-term Growth
Pillars of Near and Long-term Growth Core Business • AVONEX • TYSABRI • TECFIDERA • FAMPYRA • RITUXAN 5 New Potential Product Launches • PLEGRIDY • ELOCTATE • ALPROLIX Revitalized Pipeline & R&D • Maturing Pipeline • Advanced target discovery • Novel academic consortia • Innovative science
Slide 6: Core Products: Provide Sustainable Revenue Stream
Core Products: Provide Sustainable Revenue Stream Powerful multiple sclerosis therapy A leading worldwide therapy for multiple sclerosis First treatment indicated to improve walking in multiple sclerosis Standard of care for NHL and CLL -- Ex US -- 6 Includes Industry-leading MS Franchise Effective
Slide 7: AVONEX: Maintaining a leading position in first-line MS use
7 AVONEX: Maintaining a leading position in first-line MS use One of the most prescribed treatments for relapsing forms of MS worldwide A treatment you can start and stay on Maintaining leading position within the interferon class Convenience is key differentiator within injectable segment AVONEX Re
Slide 8: TYSABRI: Solid growth trajectory driven by powerful efficacy
TYSABRI: Solid growth trajectory driven by powerful efficacy 8 A compelling treatment option that may be considered early at the first sign of progression Proven to reduce flare-ups and slow physical disability progression Reduces ARR by 68% and EDSS by 42- 54% JCV assay is changing the treatmen
Slide 9: TYSABRI in SPMS: High Unmet Medical Need
TYSABRI in SPMS: High Unmet Medical Need ASCEND Trial Overview SPMS is a large portion of the MS market No effective therapies for SPMS Trends towards improved ambulation in patients with SPMS seen in two prior TYSABRI trials An investigation of whether TYSABRI treatment slows the accumulation of di
Slide 10: TECFIDERA: Providing a strong oral option for MS treatment
TECFIDERA (dimethyl fumarate): Providing a strong oral option for MS treatment 10 10 Strong efficacy Favorable safety profile Convenience of oral administration High physician awareness Anticipate broad appeal to a large segment of prescribing neurologists and MS patients *Under Active Review with E
Slide 11: TECFIDERA US Launch Underway
11 TECFIDERA US Launch Underway Pleased with the speed and quality of the execution by the US Commercial organization Encouraged by the early signs with both high patient and physician interest New starts coming from both naïve to therapy and patient switches Expect to be the leading oral MS
Slide 12: TECFIDERA Europe Update
12 TECFIDERA Europe Update EC Approval Now Expected 2H 2013 European TECFIDERA patent covering the 480mg dose until 2028 granted yesterday Biogen Idec working to make TECFIDERA Regulatory Data Protection clearer to all parties Goal is to launch with the strongest package in place Primary commercial
Slide 13: Pillars of Near and Long-term Growth
Pillars of Near and Long-term Growth Revitalized Pipeline & R&D • Maturing Pipeline • Advanced target discovery • Novel academic consortia • Innovative science New Potential Product Launches • PLEGRIDY • ELOCTATE • ALPROLIX Core Business • AVONEX • TYSABRI • TECFIDERA • FAMPYRA • RITUXAN 13
Slide 14: Pillars of Near and Long-term Growth
Pillars of Near and Long-term Growth New Potential Product Launches • PLEGRIDY • ELOCTATE • ALPROLIX Core Business • AVONEX • TYSABRI • TECFIDERA • FAMPYRA • RITUXAN 14 Revitalized Pipeline & R&D • Maturing Pipeline • Advanced target discovery • Novel academic consortia • Innovative science
Slide 15: PLEGRIDY: Interferon Candidate with strong potential
PLEGRIDY: Interferon Candidate with a strong potential 15 MS therapies Administration Injections per year PLEGRIDY sub-Q No more than 26 AVONEX IM 52 Rebif® sub-Q 156 Betaseron® sub-Q 182 Extavia® sub-Q 182 Copaxone® sub-Q 365 Positive Phase III (ADVANCE) trial results showed potential for every two
Slide 16: ELOCTATE: Potential first long-lasting treatment for Hemophilia A
ELOCTATE (rFVIIIFc): Potential first long-lasting treatment for Hemophilia A The extended half-life of ELOCTATE may allow for once to twice weekly prophylactic treatment Potential for prophylactic patients to reduce their injections by 50 to 100 per year Potential for episodic patients to dose once
Slide 17: ALPROLIX: Potential first long-lasting treatment for Hemophilia B
ALPROLIX (rFIXFc): Potential first long-lasting treatment for Hemophilia B ALPROLIX showed a 2.4-fold longer half-life compared to BeneFIX® in the B-LONG study Prophylactic dosing every 1-2 weeks resulted in low bleeding rates Potential to have major impact on adoption of prophylaxis Zero inhibitors
Slide 18: Pillars of Near and Long-term Growth
Pillars of Near and Long-term Growth Revitalized Pipeline & R&D • Maturing Pipeline • Advanced target discovery • Novel academic consortia • Innovative science New Potential Product Launches • PLEGRIDY • ELOCTATE • ALPROLIX Core Business • AVONEX • TYSABRI • TECFIDERA • FAMPYRA • RITUXAN 18
Slide 19: Pillars of Near and Long-term Growth
Pillars of Near and Long-term Growth New Potential Product Launches • PLEGRIDY • ELOCTATE • ALPROLIX Core Business • AVONEX • TYSABRI • TECFIDERA • FAMPYRA • RITUXAN 19 Revitalized Pipeline & R&D • Maturing Pipeline • Advanced target discovery • Novel academic consortia • Innovative science
Slide 20: Pipeline
Multiple Sclerosis (Ph. 1) Optic Neuritis (Ph. 2) Lupus Nephritis Idiopathic Pulmonary Fibrosis General Lupus Spinal Muscular Atrophy Neuropathic Pain Alzheimer's Disease Pipeline PHASE I PHASE II PHASE III FILED 20 Multiple Sclerosis Daclizumab Multiple Sclerosis TECFIDERA Hemophilia A ALPROLIX ELO
Slide 21: Pipeline Hallmarks
Pipeline Hallmarks 21 Inhibiting αvβ6 keeps TGFβ inactive, preventing fibrosis Example: STX-100 Better Drug Discovery Focus on targets with a well understood biology Use biomarkers and imaging to determine if we are hitting the target in tissue of interest Better tools to determine the best treatmen
Slide 22: A Passion for Innovative Science
A Passion for Innovative Science 22 ALS Genotyping Consortium ALS Consortium Academic Collaborations Hemophilia Genotyping Project Interactome Approaches to understand the biology of devastating diseases Collaboration with top tier academic centers Novel ALS consortium of eminent neuroscientists f
Slide 23: Biogen Idec: A Bright Future
Biogen Idec: A Bright Future 23 Strong near-term growth prospects driven by our core business Entering into an era of significant long-term growth driven by multiple potential new product launches Building an innovative pipeline to sustain longer-term value creation
Slide 24: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation 24 Condensed Consolidated Statements of Income – Operating Basis (unuadited, $ in millions, except per share amounts) FY 2007 FY 2008 FY 2009 FY 2010 FY 2011 FY 2012 GAAP diluted EPS $ 1.99 $ 2.65 $ 3.35 $ 3.94 $5.04 $5.76 Adjustment to net income attributable to Biog
Biogen Idec — 38th Annual dbAccess Health Care Conference 2013 on 6ix